Patents Assigned to Artecel Science, Inc.
-
Patent number: 9200255Abstract: The invention provides methods and compositions for differentiating stromal cells from adipose tissue into cells having osteoblastic properties, and methods for improving a subject's bone structure. The methods comprise culturing stromal cells from adipose tissue in ?-glycerophosphate and ascorbic acid and/or ascorbate-2-phosphate for a time sufficient to allow differentiation of said cells into osteoblasts. Such methods and compositions are useful in the production of osteoblasts for autologous transplantation into bone at a surgical site or injury. The compositions comprise adipose stromal cells, a medium capable of supporting the growth of fibroblasts and amounts of ?-glycerophosphate and ascorbic acid and/or ascorbic-2 phosphate sufficient to induce the differentiation of said stromal cells into osteoblasts. The invention further provides methods of identifying compounds that affect osteoblast differentiation.Type: GrantFiled: January 23, 2007Date of Patent: December 1, 2015Assignee: Artecel Sciences Inc.Inventor: Yuan-di C. Halvorsen
-
Patent number: 8911994Abstract: Methods and compositions for directing adipose-derived stromal cells cultivated in vitro to differentiate into cells of the chondrocyte lineage are disclosed. The invention further provides a variety of chondroinductive agents which can be used singly or in combination with other nutrient components to induce chondrogenesis in adipose-derived stromal cells either in cultivating monolayers or in a biocompatible lattice or matrix in a three-dimensional configuration. Use of the differentiated chondrocytes for the therapeutic treatment of a number of human conditions and diseases including repair of cartilage in vivo is disclosed.Type: GrantFiled: September 30, 2011Date of Patent: December 16, 2014Assignee: Artecel Sciences Inc.Inventors: Yuan-Di C. Halvorsen, William O. Wilkison, Jeffrey Martin Gimble
-
Patent number: 8486700Abstract: The invention relates to methods and compositions for the differentiation of stromal cells from adipose tissue into hematopoietic supporting stromal cells and myocytes of both the skeletal and smooth muscle type. The cells produced by the methods are useful in providing a source of fully differentiated and functional cells for research, transplantation and development of tissue engineering products for the treatment of human diseases and traumatic tissue injury repair.Type: GrantFiled: April 12, 2011Date of Patent: July 16, 2013Assignee: Artecel Sciences Inc.Inventors: Jeffrey Martin Gimble, Yuan-Di Chang Halvorsen, William O. Wilkison
-
Publication number: 20130017604Abstract: Methods and compositions for directing adipose-derived stromal cells cultivated in vitro to differentiate into cells of the chondrocyte lineage are disclosed. The invention further provides a variety of chondroinductive agents which can be used singly or in combination with other nutrient components to induce chondrogenesis in adipose-derived stromal cells either in cultivating monolayers or in a biocompatible lattice or matrix in a three-dimensional configuration. Use of the differentiated chondrocytes for the therapeutic treatment of a number of human conditions and diseases including repair of cartilage in vivo is disclosed.Type: ApplicationFiled: September 30, 2011Publication date: January 17, 2013Applicant: ARTECEL SCIENCES INC.Inventors: Yuan-Di C. Halvorsen, William O. Wilkison, Jeffrey Martin Gimble
-
Patent number: 8048673Abstract: Methods and compositions for directing adipose-derived stromal cells cultivated in vitro to differentiate into cells of the chondrocyte lineage are disclosed. The invention further provides a variety of chondroinductive agents which can be used singly or in combination with other nutrient components to induce chondrogenesis in adipose-derived stromal cells either in cultivating monolayers or in a biocompatible lattice or matrix in a three-dimensional configuration. Use of the differentiated chondrocytes for the therapeutic treatment of a number of human conditions and diseases including repair of cartilage in vivo is disclosed.Type: GrantFiled: April 21, 2006Date of Patent: November 1, 2011Assignee: Artecel Sciences, Inc.Inventors: Yuan-Di C. Halvorsen, William O. Wilkison, Jeffrey M. Gimble
-
Publication number: 20080038236Abstract: The present invention relates to compositions of biocompatible materials and adult stem cells. The present invention also provides methods of alleviating or treating bone defects or soft tissue defects using the compositions.Type: ApplicationFiled: March 6, 2007Publication date: February 14, 2008Applicant: Artecel Sciences, inc.Inventors: Jeffrey Gimble, David Kaplan, Joshua Mauney
-
Patent number: 7033587Abstract: Methods and compositions for directing adipose-derived stromal cells cultivated in vitro to differentiate into cells of the chondrocyte lineage are disclosed. The invention further provides a variety of chondroinductive agents which can be used singly or in combination with other nutrient components to induce chondrogenesis in adipose-derived stromal cells either in cultivating monolayers or in a biocompatible lattice or matrix in a three-dimensional configuration. Use of the differentiated chondrocytes for the therapeutic treatment of a number of human conditions and diseases including repair of cartilage in vivo is disclosed.Type: GrantFiled: November 1, 2004Date of Patent: April 25, 2006Assignee: Artecel Sciences, Inc.Inventors: Yuan-Di C. Halvorsen, William O. Wilkison, Jeffrey Martin Gimble
-
Patent number: 7001746Abstract: The present invention provides methods and compositions for the consistent and quantitative differentiation of human preadipocytes isolated from adipose tissue into adipocytes bearing biochemical, genetic, and physiological characteristics similar to that observed in isolated primary adipocytes. The methods of the invention comprise incubating isolated human preadipocytes, plated at least about 25,000 cells/cm2, in a medium containing, glucose, a cyclic AMP inducer such as isobutylmethylxanthine or forskolin, a glucocorticoid or glucocorticoid analogue, insulin or an insulin analogue and a PPAR? agonist or a RXR agonist. The compositions of the invention include media for the differentiation of human preadipocytes, human adipocytes differentiated by the methods of the invention and transfected adipocytes.Type: GrantFiled: June 1, 2000Date of Patent: February 21, 2006Assignee: Artecel Sciences, Inc.Inventors: Yuan-Di Chang Halvorsen, William O. Wilkison
-
Patent number: 6569633Abstract: The invention provides methods for identifying compounds and compositions useful in the regulation of weight, the treatment of obesity, diabetes and other insulin resistance-related disorders hypertension, cardiovascular disease and the like. The methods comprise the use of adipocytes and predipocytes in assays and screens for compounds or compositions of interest. The present invention recognizes the presence of the sulfonylurea receptor in adipocytes and its utility in identifying compounds and in treating obesity and other insulin resistance-related disorders. In addition to assaying for agonists and antagonists of the sulfonylurea receptor, the methods of the invention also provide for identifying novel calcium channels or other calcium regulatory channels that are selectively expressed in human adipocytes as compared to human preadipocytes and for screening adipocytes for compounds that selectively antagonize calcium.Type: GrantFiled: June 12, 2000Date of Patent: May 27, 2003Assignee: Artecel Science, Inc.Inventors: William O. Wilkison, Michael B. Zemel, Naima Moustaid-Moussa
-
Patent number: 6555374Abstract: The invention relates to methods and compositions for the differentiation of stromal cells from adipose tissue into hematopoietic supporting stromal cells and myocytes of both the skeletal and smooth muscle type. The cells produced by the methods are useful in providing a source of fully differentiated and functional cells for research, transplantation and development of tissue engineering products for the treatment of human diseases and traumatic tissue injury repair.Type: GrantFiled: August 14, 2000Date of Patent: April 29, 2003Assignee: Artecel Sciences, Inc.Inventors: Jeffrey Martin Gimble, Juan-Di Chang Halvorsen, William O. Wilkison
-
Patent number: 6492130Abstract: The invention provides methods for determining the ability of compounds to regulate lipogenesis and lipolysis by acting as a sulfonylurea-1 (SUR 1) potassium channel activator, an adipocyte potassium channel activator, an SUR 1 antagonist, and an adipocyte specific SUR 1 antagonist. The present invention recognizes the presence of the sulfonylurea receptor in adipocytes and its utility in identifying compounds and in regulating lipogenesis and lipolysis.Type: GrantFiled: June 12, 2000Date of Patent: December 10, 2002Assignee: Artecel Sciences, Inc.Inventors: William O. Wilkison, Michael B. Zemel, Naima Moustaid-Moussa
-
Patent number: 6429013Abstract: Methods and compositions for directing adipose-derived stromal cells cultivated in vitro to differentiate into cells of the chondrocyte lineage are disclosed. The invention further provides a variety of chondroinductive agents which can be used singly or in combination with other nutrient components to induce chondrogenesis in adipose-derived stromal cells either in cultivating monolayers or in a biocompatible lattice or matrix in a three-dimensional configuration. Use of the differentiated chondrocytes for the therapeutic treatment of a number of human conditions and diseases including repair of cartilage in vivo is disclosed.Type: GrantFiled: May 17, 2000Date of Patent: August 6, 2002Assignee: Artecel Science, Inc.Inventors: Yuan-Di C. Halvorsen, William O. Wilkison, Jeffrey Martin Gimble
-
Patent number: 6391297Abstract: The invention provides a composition of an isolated human adipose tissue-derived stromal cell that has been differentiated to exhibit at least one characteristic of a non-adipocyte cell lineage wherein the non-adipocyte cell lineage is osteoblastic. The adipose-derived cell possessing an osteoblastic characteristic can be genetically modified or combined with a matrix. The compositions of the invention can be used in vivo to repair bone and treat bone diseases.Type: GrantFiled: May 19, 2000Date of Patent: May 21, 2002Assignee: Artecel Sciences, Inc.Inventor: Yuan-di C. Halvorsen